Once‐weekly semaglutide use in patients with type 2 diabetes: Real‐world data from the SURE Italy observational study
Open accessThe DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
Aims: SURE Italy, a multicentre, prospective, open‐label, observational, real‐world study, investigated once‐weekly semaglutide in patients with type 2 diabetes (T2D) in routine clinical practice. Materials and Methods: Adults with T2D and ≥1 documented glycated haemoglobin (HbA1c) level within 12 weeks of semaglutide initiation were enrolled. The primary endpoint was change in HbA1c from baseline to end of study (EOS; ~30 weeks). Other endpoints included changes in body weight, waist circumference and patient‐reported outcomes, and the proportion of patients achieving HbA1c <7.0% or <6.5%, weight loss ≥5% and a post‐hoc composite endpoint (HbA1c reduction of ≥1%‐point and weight loss ≥5%). These endpoints were reported for patients on semaglutide at EOS [effectiveness analysis set (EAS)]. Safety data were reported in the full analysis set. Results: Of 579 patients who initiated semaglutide (full analysis set), 491 completed the study on treatment (EAS). Mean baseline HbA1c was 8.0%, and 20.7% (120 of 579) of patients had HbA1c <7.0%. Mean semaglutide dose at EOS was 0.66 ± 0.28 mg. In the EAS, mean HbA1c and body weight decreased by 1.1%‐point (95% confidence interval 1.20, 1.05; P < .0001) and 4.2 kg (95% confidence interval 4.63, 3.67; P < .0001), respectively. At EOS, 61.7% and 40.8% of patients achieved HbA1c <7.0% and <6.5%, respectively, 40.5% achieved weight loss ≥5% and 25.3% achieved the post‐hoc composite endpoint. Patient‐reported outcomes improved from baseline to EOS. No new safety concerns were identified. Conclusions: In routine clinical practice in Italy, patients with T2D treated with once‐weekly semaglutide for 30 weeks achieved clinically significant improvements in HbA1c, body weight and other outcomes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Davies, M. J., Aroda, V. R., Collins, B. S., Gabbay, R. A., Green, J., Maruthur, N. M., Rosas, S. E., Del Prato, S., Mathieu, C., Mingrone, G., et al. (2022) · Diabetes Care · doi:10.2337/dci22-0034 · Cited by 2,104 · cited 1×
“Yet, few patients in Italy are treated with SGLT2is or GLP-1RAs, in contrast with current national and international guidelines.(2,3,6,7) However, the study presented herein was based on the then current 2018 Italian guidelines,(10) which recommended GLP-1RAs as second-line therapy after metformin, regardless of patie…”
Result9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2022
American Diabetes Association Professional Practice Committee (2022) · Diabetes Care · doi:10.2337/dc22-s009 · Cited by 1,555 · cited 2×
“However, discontinuation of DPP-4i treatment is recommended when adding GLP-1RA, because of overlapping mechanisms of action.(34) DPP-4is block DPP-4 from degrading GLP-1, increasing endogenous levels of GLP-1, whereas GLP-1RAs mimic the stimulatory effects of GLP-1.”
BackgroundMethodDiscovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide
Lau, J., Bloch, P., Schäffer, L., Pettersson, I., Spetzler, J., Kofoed, J., Madsen, K., Knudsen, L. B., McGuire, J., Steensgaard, D. B., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00726 · Cited by 1,105 · cited 1×
“0 mg, has been approved by many regulatory agencies for treating adults with T2D, in addition to diet and exercise.(11,12) Compared with placebo and many active comparators, OW semaglutide showed superior, clinically relevant reductions in glycated haemoglobin (HbA1c) and body weight in the SUSTAIN clinical trials, wi…”
Background10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes—2022
American Diabetes Association Professional Practice Committee (2022) · Diabetes Care · doi:10.2337/dc22-s010 · Cited by 869
Sorli, C., Harashima, S.-I., Tsoukas, G. M., Unger, J., Karsbøl, J. D., Hansen, T., & Bain, S. C. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30013-x · Cited by 745
Ahmann, A. J., Capehorn, M., Charpentier, G., Dotta, F., Henkel, E., Lingvay, I., Holst, A. G., Annett, M. P., & Aroda, V. R. (2018) · Diabetes Care · doi:10.2337/dc17-0417 · Cited by 596
Ahrén, B., Masmiquel, L., Kumar, H., Sargin, M., Karsbøl, J. D., Jacobsen, S. H., & Chow, F. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30092-x · Cited by 495
10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023
ElSayed, N. A., Aleppo, G., Aroda, V. R., Bannuru, R. R., Brown, F. M., Bruemmer, D., Collins, B. S., Das, S. R., Hilliard, M. E., Isaacs, D., et al. (2023) · Diabetes Care · doi:10.2337/dc23-s010 · Cited by 465
Semaglutide added to basal insulin in type 2 diabetes (SUSTAIN 5): a randomized, controlled trial.
Rodbard, H. W., Lingvay, I., Reed, J., de la Rosa, R., Rose, L., Sugimoto, D., Araki, E., Chu, P.-L., Wijayasinghe, N., & Norwood, P. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-00070 · Cited by 412
The anti-inflammatory and immunological properties of GLP-1 Receptor Agonists
Bendotti, G., Montefusco, L., Lunati, M. E., Usuelli, V., Pastore, I., Lazzaroni, E., Assi, E., Seelam, A. J., El Essawy, B., Jang, J., et al. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106320 · Cited by 406 · cited 1×
“Specifically, GLP-1RAs lower CV risk factors, such as blood pressure,(8) and act on inflammation.(9)”
BackgroundSelf-citationRajamand Ekberg, N., Bodholdt, U., Catarig, A.-M., Catrina, S.-B., Grau, K., Holmberg, C. N., Klanger, B., & Knudsen, S. T. (2021) · Primary Care Diabetes · doi:10.1016/j.pcd.2021.06.008 · Cited by 63
Self-citationYale, J.-F., Bodholdt, U., Catarig, A.-M., Catrina, S., Clark, A., Ekberg, N. R., Erhan, U., Holmes, P., Knudsen, S. T., Liutkus, J., et al. (2022) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2021-002619 · Cited by 50
Self-citationRudofsky, G., Catarig, A.-M., Favre, L., Grau, K., Häfliger, S., Thomann, R., & Schultes, B. (2021) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.108931 · Cited by 46
Self-citationHolmes, P., Bell, H. E., Bozkurt, K., Catarig, A.-M., Clark, A., Machell, A., & Sathyapalan, T. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01141-8 · Cited by 42
Self-citationMarzullo, P., Daffara, T., Mele, C., Zavattaro, M., Ferrero, A., Caputo, M., Prodam, F., & Aimaretti, G. (2022) · Journal of Endocrinological Investigation · doi:10.1007/s40618-022-01799-2 · Cited by 34
Effects of semaglutide on cardiovascular risk factors and eating behaviors in type 2 diabetes
Di Folco, U., Vallecorsa, N., Nardone, M. R., Pantano, A. L., & Tubili, C. (2022) · Acta Diabetologica · doi:10.1007/s00592-022-01936-6 · Cited by 29
Research works printed but not linked: 18
- International Diabetes Federation.IDF Diabetes Atlas 10th Edition. Accessed November 15 2022.https://diabetesatlas.org/idfawp/resource-files/2021/07/IDF_Atlas_10th_Edition_2021.pdf
- 10.1016/j.numecd.2022.01.026 · DOI
- 10.2337/dc23-S004 · DOI · Paper page
- 10.1007/s00592-022-01857-4 · DOI
- 10.1016/j.phrs.2020.105052 · DOI
- 10.1016/S2213-8587(17)30085-2 · DOI · Paper page
- 10.1016/S2213-8587(18)30024-X · DOI · Paper page
- 10.1007/s12325-018-0805-y · DOI · Paper page
- 10.1001/jama.2013.281053 · DOI · Paper page
- 10.1002/pds.1471 · DOI · Paper page
- 10.1111/dom.14468 · DOI · Paper page
- 10.3390/jcm11174938 · DOI
- 10.1007/s13300-022-01218-y · DOI · Paper page
- 10.3389/fendo.2022.892702 · DOI
- 10.36171/jamd22.25.2.5 · DOI
- 10.1007/s13300-020-00984-x · DOI · Paper page
- 10.1210/10.1210/er.2006-0038 · DOI · Paper page
- 10.1111/dom.14765 · DOI · Paper page
Cited by
Semaglutide and cancer: A systematic review and meta-analysis
Nagendra, L., BG, H., Sharma, M., & Dutta, D. (2023) · Diabetes & Metabolic Syndrome: Clinical Research & Reviews · doi:10.1016/j.dsx.2023.102834 · Cited by 86
Chen, Y.-K., Liu, T.-T., Teia, F. K. F., & Xie, M.-Z. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1218880 · Cited by 74
Caballero Mateos, I., García de Lucas, M. D., Doulatram-Gamgaram, V. K., Moreno-Moreno, P., Jimenez-Millan, A. I., Botana-López, M., Merino-Torres, J. F., Soto-Gónzalez, A., Fernández-García, J. C., & Morales-Portillo, C. (2024) · Nutrients · doi:10.3390/nu16152545 · Cited by 8
Rudofsky, G., Menzen, M., Potier, L., Catarig, A.-M., Clark, A., Priyadarshini, P., & Abreu, C. (2025) · Advances in Therapy · doi:10.1007/s12325-024-03000-x · Cited by 3
Self-citation
Metadata
- Authors
- Napoli, R., Berra, C., Catarig, A., Di Loreto, C., Donatiello, E., Berentzen, T. L., Pitocco, D., & Giorgino, F.
- Venue
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Published
- 2023-03-12
- Volume
- 25
- Issue
- 6
- Pages
- 1658-1667
- ISSN
- 1462-8902 (ISSN-L)
- 1463-1326
- OpenAlex
- W4320855956
- Cited by
- 32
- References
- 16
- FWCI
- 5.29
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.